SHR-1826 + ametinib

SHR-1826 + ametinib is a **combination therapy** currently under clinical investigation for the treatment of advanced solid tumors, including non-small cell lung cancer. SHR-1826 is an antibody-drug conjugate targeting c-Met (hepatocyte growth factor receptor), with a topoisomerase I inhibitor payload that is internalized into cancer cells, resulting in cytotoxicity. It has shown promising results for MET-altered NSCLC. Ametinib is a small molecule tyrosine kinase inhibitor targeting EGFR (epidermal growth factor receptor) mutations, which are common in lung cancer. The combination aims to enhance antitumor efficacy by simultaneously targeting both c-Met and EGFR pathways, potentially overcoming resistance mechanisms to single-agent therapies[1][2][4][5][6].

Other names

SHR-1826SHR1826SHR 1826ametinib